Close Menu

cytogenetics

This story was originally posted on June 17.

Name: Marilyn Li
Title: Director, Cancer Genetics Laboratory, Baylor College of Medicine

The market for microarrays continues to grow, thanks to demand from direct-to-consumer genetics companies, as well as researchers who now favor using lower-complexity arrays in larger studies, according to Illumina CEO Jay Flatley.

Members of the International Collaboration for Clinical Genetics gathered earlier this month to discuss the aims of a proposed effort to develop a database of genomic variation.

This article was originally posted on May 1.
An unanticipated decline in demand for gene expression microarrays has thwarted Affymetrix's return to growth and profitability and caused the firm to suspend its 2013 guidance, executives said last week.

Illumina's microarray revenues increased 1 percent in the first quarter due to demand from consumer genetics companies, researchers running genome-wide association studies, and clients of BlueGnome's chips for cytogenetics and pre-implantation genetic diagnosis, the company said

Illumina and Kindstar Global announced last week that they have made an agreement that allows Kindstar to offer a set of Illumina products, including the Infinium Dx CytoSNP-12 BeadChip assay, to its Chinese clients.

Oxford Gene Technology said this week that it has signed an agreement with the Cancer Cytogenomics Microarray Consortium to use the organization's suggested cancer array design to develop and launch its own whole-genome, cancer-specific chip.

Cancer Genetics this week said that its microarray-based test for diagnosing and monitoring diffuse large B-cell lymphoma has been deemed by regulatory authorities to be compliant with the US Clinical Laboratory Improvement Amendments as well as New York State regulations.

Pages

The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.

According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.

New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.

In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.